Drug intelligence / Profile preview

furosemide + isosorbide dinitrate

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous, Oral, Sublingual

Overview

Combination of furosemide, a loop diuretic, and isosorbide dinitrate, a vasodilator. Furosemide works by inhibiting sodium and chloride resorption in the ascending limb of the loop of Henle, increasing urine production and reducing fluid volume. Isosorbide dinitrate relaxes vascular smooth muscle, causing dilation of peripheral arteries and veins, which reduces preload and afterload on the heart. This combination is primarily used in the treatment of severe pulmonary edema and heart failure.

Targets

sGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on furosemide + isosorbide dinitrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on furosemide + isosorbide dinitrate.

Explore the full profile